Literature DB >> 12714503

RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement.

Branka Roscic-Mrkic1, Marek Fischer, Christine Leemann, Amapola Manrique, Cynthia J Gordon, John P Moore, Amanda E I Proudfoot, Alexandra Trkola.   

Abstract

The CC-chemokine RANTES (regulated on activation normal T-cell expressed and secreted; CCL5) transduces multiple intracellular signals. Like all chemokines, it stimulates G protein-coupled receptor (GPCR) activity through interaction with its cognate chemokine receptor(s), but in addition also activates a GPCR-independent signaling pathway. Here, we show that the latter pathway is mediated by an interaction between RANTES and glycosaminoglycan chains of CD44. We provide evidence that this association, at both low, physiologically relevant, and higher, probably supraphysiologic concentrations of RANTES, induces the formation of a signaling complex composed of CD44, src kinases, and adapter molecules. This triggers the activation of the p44/42 mitogen-activated protein kinase (MAPK) pathway. By specifically reducing CD44 expression using RNA interference we were able to demonstrate that the p44/p42 MAPK activation by RANTES requires a high level of CD44 expression. As well as potently inhibiting the entry of CCR5 using HIV-1 strains, RANTES can enhance HIV-1 infectivity under certain experimental conditions. This enhancement process depends in part on the activation of p44/p42 MAPK. Here we show that silencing of CD44 in HeLa-CD4 cells prevents the activation of p44/p42 MAPK and leads to a substantial reduction in HIV-1 infectivity enhancement by RANTES.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12714503     DOI: 10.1182/blood-2003-02-0488

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  39 in total

1.  Rantes/Ccl5 influences hematopoietic stem cell subtypes and causes myeloid skewing.

Authors:  Aysegul V Ergen; Nathan C Boles; Margaret A Goodell
Journal:  Blood       Date:  2012-01-30       Impact factor: 22.113

2.  Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked.

Authors:  Michael Huber; Viktor von Wyl; Christoph G Ammann; Herbert Kuster; Gabriela Stiegler; Hermann Katinger; Rainer Weber; Marek Fischer; Heribert Stoiber; Huldrych F Günthard; Alexandra Trkola
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

3.  Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide.

Authors:  Hubert Gaertner; Fabrice Cerini; Jean-Michel Escola; Gabriel Kuenzi; Astrid Melotti; Robin Offord; Irène Rossitto-Borlat; Rebecca Nedellec; Janelle Salkowitz; Guy Gorochov; Donald Mosier; Oliver Hartley
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-12       Impact factor: 11.205

4.  HIV-1 p17 matrix protein interacts with heparan sulfate side chain of CD44v3, syndecan-2, and syndecan-4 proteoglycans expressed on human activated CD4+ T cells affecting tumor necrosis factor alpha and interleukin 2 production.

Authors:  Maria A De Francesco; Manuela Baronio; Claudio Poiesi
Journal:  J Biol Chem       Date:  2011-04-11       Impact factor: 5.157

5.  HIV-1 glycoprotein 41 ectodomain induces activation of the CD74 protein-mediated extracellular signal-regulated kinase/mitogen-activated protein kinase pathway to enhance viral infection.

Authors:  Chang Zhou; Lu Lu; Suiyi Tan; Shibo Jiang; Ying-Hua Chen
Journal:  J Biol Chem       Date:  2011-10-28       Impact factor: 5.157

Review 6.  Chemokine-like functions of MIF in atherosclerosis.

Authors:  Andreas Schober; Jürgen Bernhagen; Christian Weber
Journal:  J Mol Med (Berl)       Date:  2008-04-02       Impact factor: 4.599

7.  Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection.

Authors:  Adrian Schmid; Sara Gianella; Viktor von Wyl; Karin J Metzner; Alexandra U Scherrer; Barbara Niederöst; Claudia F Althaus; Philip Rieder; Christina Grube; Beda Joos; Rainer Weber; Marek Fischer; Huldrych F Günthard
Journal:  PLoS One       Date:  2010-10-12       Impact factor: 3.240

8.  Dose-responsive gene expression in suberoylanilide hydroxamic acid-treated resting CD4+ T cells.

Authors:  Brian Reardon; Nadejda Beliakova-Bethell; Celsa A Spina; Akul Singhania; David M Margolis; Douglas R Richman; Christopher H Woelk
Journal:  AIDS       Date:  2015-11       Impact factor: 4.177

9.  Structural basis for oligomerization and glycosaminoglycan binding of CCL5 and CCL3.

Authors:  Wenguang G Liang; Catherine G Triandafillou; Teng-Yi Huang; Medel Manuel L Zulueta; Shiladitya Banerjee; Aaron R Dinner; Shang-Cheng Hung; Wei-Jen Tang
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-18       Impact factor: 11.205

10.  Dose dependent effects of platelet derived chondroitinsulfate A on the binding of CCL5 to endothelial cells.

Authors:  Christian Weingart; Peter J Nelson; Bernhard K Krämer; Matthias Mack
Journal:  BMC Immunol       Date:  2008-12-10       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.